StrongBox Wealth LLC Acquires 6,085 Shares of Kenvue Inc. (NYSE:KVUE)

StrongBox Wealth LLC grew its position in Kenvue Inc. (NYSE:KVUE) by 8.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,057 shares of the company’s stock after purchasing an additional 6,085 shares during the period. StrongBox Wealth LLC’s holdings in Kenvue were worth $1,752,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of KVUE. Riverview Trust Co bought a new stake in shares of Kenvue in the third quarter valued at about $30,000. Fortitude Family Office LLC lifted its holdings in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the third quarter valued at about $35,000. Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after acquiring an additional 651 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $20.83 on Thursday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The business’s 50 day moving average price is $22.50 and its two-hundred day moving average price is $21.64. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a market cap of $39.94 billion, a PE ratio of 37.87, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the business earned $0.31 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on KVUE. Jefferies Financial Group began coverage on Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Barclays raised Kenvue to a “hold” rating in a research report on Thursday, December 12th. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.